Fennec Pharmaceuticals Inc. (FENC) Stock Analysis & Investment Frameworks
Fennec Pharmaceuticals Inc. (FENC) stock analysis on Invetso. Review Fennec Pharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Fennec Pharmaceuticals Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Fennec Pharmaceuticals Inc. Key Financial Metrics
- Market Cap: $344.01M
- Revenue: $44.64M
- ROE: -11.71%
- ROIC: -1.84%
- Dividend Yield: N/A
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.